A Concise Synthesis of the Anthraquinone Portion of Dynemicin A

Philip Magnus,* Shane A. Eisenbeis and Nicholas A. Magnus

Department of Chemistry and Biochemistry, University of Texas at Austin, Austin, Texas 78712, USA


Addition of the lactone anion derived from **29** to **13** gave the adduct **30**, which was dehydrated to give **20**; subsequent conversion of **20** into the anthraquinone **26** was achieved in two steps.

The recently isolated antitumour antibiotic dynemicin A 1, and its derived acetate 2, have attracted considerable synthetic interest because of their unusual structures, potent antitumour activity, and speculated *in vitro* mechanism of action.¹ We have synthesized the core azabicyclo[7.3.1]enediyne core structure 3, and have found that it shows both *in vitro* and *in vivo* antitumour activity even though it does not cycloaromatize via a 1,4-diyl to give 3a until heated to >90 °C.² This demonstrated that the widely accepted assumption that the 1,4-diyl (diradical) formed under physiological conditions is necessary for biological activity, is not valid.³ Both natural, and simpler synthetic anthraquinones, frequently exhibit potent antitumour activity.⁴ Therefore it seemed reasonable to see if the anthraquinone portion of dynemicin A 1 displayed any antitumour activity.


Incorporating the core structure 3 into the anthraquinone results in 4, and the anthraquinone core portion is 5 (Scheme 1). There have been reports of the synthesis of the anthraquinone portions of dynemicin A, and the synthesis of di-O-methyl dynemicin.⁵ The parent quinone 5 has not been described.

While numerous methods have been used for the synthesis of anthraquinones, we focused on the Snieckus strategy since it appeared to offer the most direct route.⁶ We have examined this strategy at different oxidation levels in order to assess which would be the most convenient.

A general convergent retrosynthetic pathway (Scheme 2) requires the synthesis of two components; the 4,7-dimethoxyisobenzofuran 10, and a 3-methylpyridine dienophile 9. It was



Scheme 1 Conditions: i, >90 °C




Scheme 2

anticipated that the cycloaddition adduct 8 could be aromatized to give 7. Treatment of 7 with an amide base would result in formation of the 3-methylpyridine anion which should cyclize to give 6. Subsequent oxidation would provide the anthraquinone core structure of dynemicin A.

4,7-Dimethoxyisobenzofuran 10 was prepared by treatment of the furan 1,4-dimethoxybenzyne adduct it with 1,4-dipyridyltetrazine ii, and isolated as a moderately stable crystalline solid. 3-Methyl-2-pyridine carboxaldehyde 11 was converted into the acetylenic ester 12 (Scheme 3) and treated with 10 to give the adduct 14 (>95%). The adduct 14 was readily aromatized to a mixture of 17 and 18 when treated with TBSOTf-CH₂Cl₂ (>95%, 5:1). Similarly, treatment of 13 with 10 gave the two cycloaddition adducts 15 and 16 (>95%), 2:1). The major adduct 16 was separated by crystallization (structure by X-ray diffraction). It proved to be extremely resistant to aromatization using acidic conditions, but upon treatment with lithium diisopropylamide at -78 °C was converted into the naphthalene derivative 19. Continued exposure of 19 to the above conditions, but with warming to 50 °C, resulted in cyclization to give 24 (90%, after pivaloylation). Interestingly, the minor adduct 15 was inert to these aromatization conditions.

When the TBDMS protected derivatives 17 and 18 were treated with lithium diisopropylamide in THF at 25 °C, followed by Bu^tCOCl, they were converted into the anthracene derivatives 21 and 22 respectively [(72%), only 21 formed a pivaloate derivative]. The mixture of 21 and 22 was readily oxidized to the anthraquinone 25 (72%, Ag^{II}O, HNO₃-dioxane, 22 was destroyed).⁷ The compound 24 was preferentially oxidized in the terminal ring to give 28, (Scheme 4). While the route to 25 is short, we also explored a regiospecific route that avoided the use of 4,7-dimethoxyisobenzofuran.

o-Lithiation of 2,5-dimethoxybenzyl alcohol using *n*-butyllithium in THF at reflux, followed by quenching the resulting dianion with carbon dioxide and acidification, gave the lactone **29** (80%).⁸ Addition of the lactone **29** to a solution of lithium diisopropylamide in THF, followed by the α , β -unsaturated ester **13** gave the adduct **30** (and stereoisomer) in excellent



Scheme 3 Reagents and conditions: i, CBr_4 -Ph₃P-NEt₃-CH₂Cl₂ (71%) then LiN(SiMe₃)₂ (1.2 equiv.)-BuⁿLi (2.1 equiv.)-THF -78 °C, inverse addition to ClCO₂Me (3.0 equiv.)-THF, -78 °C (95%), ii, (EtO)₂POCH₂CO₂Et-NaH-THF (95%); iii, 10-PhH, reflux 10 h (95%); iv, 10-PhH, 25 °C (90%); v, TBSOTf (10 equiv.)-2,6-lutidine (20 equiv.) -CH₂Cl₂ (95%); vi, LiNPri₂-THF, -78 °C


1546

yield. Exposure of 30 to toluene-p-sulfonic acid in chloroform at 25 °C resulted in clean aromatization to give, after pivaloylation, the naphthalene derivative 20 (87% from 30), (Scheme 5). When the derived pivaloyl ester derivative 20 was treated with lithium diisopropylamide in THF at 50 °C it was converted into the anthracene 23 (95%). Presumably, the origin of the ethyl ether 23 is via the intermediate ortho-ester 23a, which prefers to eliminate pivaloate anion rather than ethoxide anion, thus providing an unexpected in situ protection of the newly formed anthracene 23.


Oxidation of 23 with ceric ammonium nitrate in MeCN- H_2O gave the anthraquinone 26 as an orange crystalline solid (72%).9 Deprotection of 26 to give 27 was accomplished using hydrogen bromide acid in acetic acid heated at reflux, (Scheme 4).

The insoluble blue-violet trihydroxyanthraquinone 5 was characterized as its derived triacetate 27 (Ac₂O-pyridine). The overall route to the triacetoxyanthraquinone 28 is very short [five steps via 31, 20, 24 and 25/26], and currently several of these quinones are undergoing biological evaluation.

The National Institutes of Health, National Science Foun-



Scheme 4 Reagents and conditions: i, LiNPri2 (5.0 equiv.)-THF, 0–25 °C then Bu^tCOCl (20 equiv.)–pyridine (40 equiv.)–CH₂Cl₂ (72%); ii, Ag^{II}O (4.0 equiv.)–dioxane–6 mol dm⁻³ HNO₃ (cat) (72%) or Ce(NH₄)₂(NO₂)₆-MeCN; iii, HBr-AcOH, Ac₂O, pyridine (75%)




Scheme 5 Reagents and conditions: i, BunLi (2.5 equiv.)-THF, -70 to 50 °C, 3 h, CO₂, 2 mol dm⁻³ HCl (80%); ii, LiNPrⁱ₂ (2.0 equiv.)–THF, -78 °C, **13** (>95%); iii, *p*-TsOH–CHCl₃ then Bu⁴COCl–CH₂Cl₂– Et₃N (87%)

dation and Bristol-Myers Squibb are thanked for their financial support.

Received, 15th March 1994; Com. 4/01561D

Footnote

† 4,7-Dimethoxyisobenzofuran 10 was made by treatment of i with the tetrazine ii (R = 2-pyridyl). While 10 has been reported as an intermediate in various [2+4] cycloaddition reactions, it has not been previously isolated presumably because of its assumed instability. For the synthesis of i see: G. M. L. Cragg, R. G. F. Giles and G. P. H. Roos, J. Chem. Soc. Perkin Trans. 1, 1975, 339; ii, J. F. Geldard and F. Lions, J. Org. Chem., 1965, 30, 318.



i, THF, NaNH₂, furan, 3 h

References

- 1 M. Konishi, H. Ohkuma, K. Matsumoto, T. Tsuno, H. Kamei, T. Miyaki, T. Oki, H. Kawaguchi, G. D. Van Duyne and J. Clardy, J. Antibiot., 1989, 42, 1449; M. Konishi, H. Ohkuma, T. Tsuno, T. Oki, G. D. Van Duyne and J. Clardy, J. Am. Chem. Soc., 1990, 112, 3715; molecular modelling of the dynemicin-DNA complex predicts the absolute configuration to be 2S, 3S, 4S, 7R, 8R, D. R. Langley, T. W. Doyle and D. L. Beveridge, J. Am. Chem. Soc., 1991, 113, 4395.
- 2 P. Magnus and S. A. Eisenbeis, J. Am. Chem. Soc., 1993, 115, 12627; P. Magnus and S. M. Fortt, J. Chem. Soc., Chem. Commun., 1991, 544.
- 3 K. C. Nicolaou and W.-M. Dai, Angew. Chem., Int. Ed. Engl., 1991, 1387; K. C. Nicolaou, A. L. Smith, C.-K. Hwang and S. V. Wendeborn, J. Am. Chem. Soc., 1991, 113, 3114; K. C. Nicolaou, A. L. Z. Zeng and S. McComb, J. Am. Chem. Soc., 1992, 114, 9279.
- 4 H. D. H. Showalter, J. L. Johnson and J. M. Hoftiezer, J. Heterocycl. Chem., 1986, 23, 1491; H. D. H. Showalter, J. L. Johnson, J. M. Hoftiezer, W. R. Turner, L. M. Werbel, W. R. Leopold, J. L. Shillis, R. C. Jackson and E. F. Elslager, J. Med. Chem., 1987, 30, 121.
- 5 H. Chikashita, J. A. Porco, Jr., T. J. Stout, J. Clardy and S. L. Schreiber, J. Org. Chem., 1991, 56, 1692; J. Taunton, J. L. Wood and S. L. Schreiber, J. Am. Chem. Soc., 1993, 115, 10378.
- M. A. F. Brandão, A. B. de Oliveira and V. Snieckus, Tetrahedron Lett., 1993, 34, 2437.
- C. D. Snyder and H. Rapoport, J. Am. Chem. Soc., 1972, 94, 227
- 8 D. J. Dodsworth, M. Calcagno, E. U. Ehrmann, B. Devadas and P. G. Sammes, J. Chem. Soc., Perkin Trans. 1, 1981, 2120.
- 9 T.-L. Ho, T.-W. Hall and C. M. Wong, Synthesis, 1973, 206.